Page 14 - Binder1

CV247 Therapy

CV247 therapy supports the antioxidant processes and the immune system in the body, and thereby improves the quality of life of cancer patients and slows or
stops the progression of cancer or may even induce the regression of some tumours.

Four types of malignancies, breast, colon, prostate and lung carcinoma were selected for testing the action of CV247 therapy against its individual components and
against ascending dilutions of cisplatin with three cell lines for each type. With flow cytometry, ATP‐TCA luminometry, sulpho‐rhodamine B assay and Crystal
Violet assay, the viability and cell toxicity of the cultures was measured by determining necrotic, apoptotic and viable cells before and after CV247 therapy. The
combination of these techniques provided solid scientific evidence because the advantage of the one technique overlapped the disadvantage of the others,
and hence the results were reliable.

The results clearly supported the benefit of the combination in CV247 therapy compared with its individual components. Most exhibited an increase in dead cells
and cells apparently halted in the G2 phase of mitosis. This was in contrast to their controls, indicating a cytotoxic effect of a more gradual and sustained type than
seen with traditional cytotoxic drugs which have a rapid onset, rarely kill tumour stem cells and often inhibit tumour cells for only short periods. This was
particularly marked in LoVo colonic cancer and T47D breast cancer cell lines where CV247 therapy was considerably more active than Na salicilate alone.

CV247 therapy is a combination product comprising of Sodium Salicylate, Copper Gluconate, Manganese Gluconate and Ascorbic Acid (Vitamin C) taken in the
form of two tablets. The product was conceived and initially developed by John Carter MRCVS, a veterinary surgeon, who also advocated that in combination with
the therapy a patient also followed an organic and healthy diet.

Sodium Salicylate is a non‐steroidal anti‐inflammatory drug (NSAID); evidence suggests their inhibition of prostaglandin (PGE2) synthesis and inhibition of COX
enzymes mediates their anti‐inflammatory properties. Inhibition of COX and PGE2 is thought to be anti‐angiogenic, and stimulatory of anti‐tumour immuno‐
surveillance and inhibitory of tumour cell migration [36‐39].

The minerals Manganese and Copper contribute to the immune‐supportive properties of CV247 therapy. Both are essential in the functioning of anti‐oxidant
enzymes, including Superoxide dismutases (SODs). Manganese and Copper are essential trace elements needed for the functioning of several enzymes promoting
immunity and biochemical functions including the prevention of oxidation. These enzymes malfunction in malignant disease and allow oxidative DNA damage.